The transaction, completed on August 18, 2026, integrates Yapan Bio’s specialized expertise in vaccine and biologics manufacturing directly into the structure of Piramal Pharma Solutions (PPS). By bringing these advanced large molecule capabilities under its corporate umbrella, Piramal aims to accelerate the development and scaling of complex therapies for its global client base.

This move strengthens the ADCelerate™ platform, a fixed-price service designed to fast-track Phase I antibody-drug conjugate development from initial research to GMP manufacturing within 12 months. Peter DeYoung, CEO of Piramal Global Pharma, stated that the acquisition aligns with the company’s long-term growth strategy and commitment to patient-centric drug development. Yapan Bio has been a key partner for Piramal since 2021, and this new ownership structure is expected to streamline the delivery of life-saving biologics to markets worldwide.